Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer
Karine Pozo(The University of Texas Southwestern Medical Center), James Bibb(University of Arizona)
Cited by 6
Related Papers
Memory Enhancement by Targeting Cdk5 Regulation of NR2B
|Neuron|2014|133
Attention-Deficit/Hyperactivity Phenotype in Mice Lacking the Cyclin-Dependent Kinase 5 Cofactor p35
|Biological Psychiatry|2010|58
Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis
|Oncotarget|2015|30
Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
|Frontiers in Pharmacology|2022|22